Consistent with the aforementioned results, patients with lower UGP2 expression levels had a shorter survival time than those with higher UGP2 expression levels (P = 0.003; Figure 5(a)), and the OS of HCC patients with lower UGP2 expression levels was shorter regardless of the TNM stage (TNM I/II: P = 0.048; TNM III/IV: P = 0.043; Figure 5(b)). Here, UGP2 is linked to hepatocellular carcinoma.